Literature DB >> 17050593

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Sanae Sasaki1, Maria C Jaimes, Tyson H Holmes, Cornelia L Dekker, Kutubuddin Mahmood, George W Kemble, Ann M Arvin, Harry B Greenberg.   

Abstract

Cellular immune responses to influenza virus infection and influenza virus vaccination have not been rigorously characterized. We quantified the effector and memory B-cell responses in children and adults after administration of either live attenuated (LAIV) or inactivated (TIV) influenza virus vaccines and compared these to antibody responses. Peripheral blood mononuclear cells were collected at days 0, 7 to 12, and 27 to 42 after immunization of younger children (6 months to 4 years old), older children (5 to 9 years old), and adults. Influenza virus-specific effector immunoglobulin A (IgA) and IgG circulating antibody-secreting cells (ASC) and stimulated memory B cells were detected using an enzyme-linked immunospot assay. Circulating influenza virus-specific IgG and IgA ASC were detected 7 to 12 days after TIV and after LAIV immunization. Seventy-nine percent or more of adults and older children had demonstrable IgG ASC responses, while IgA ASC responses were detected in 29 to 53% of the subjects. The IgG ASC response rate to LAIV immunization in adults was significantly higher than the response rate measured by standard serum antibody assays (26.3% and 15.8% by neutralization and hemagglutination inhibition assays, respectively). IgG ASC and serum antibody responses were relatively low in the younger children compared to older children and adults. TIV, but not LAIV, significantly increased the percentage of circulating influenza virus-specific memory B cells detected at 27 to 42 days after immunization in children and adults. In conclusion, although both influenza vaccines are effective, we found significant differences in the B-cell and antibody responses elicited after LAIV or TIV immunization in adults and older children and between young children and older age groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050593      PMCID: PMC1797237          DOI: 10.1128/JVI.01957-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system.

Authors:  Shane Crotty; Rachael D Aubert; John Glidewell; Rafi Ahmed
Journal:  J Immunol Methods       Date:  2004-03       Impact factor: 2.303

2.  Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain.

Authors:  Paul M Mendelman; Ruth Rappaport; Iksung Cho; Stan Block; William Gruber; Marilyn August; Denise Dawson; Julie Cordova; George Kemble; Kutubuddin Mahmood; Giuseppe Palladino; Min-Shi Lee; Ahmad Razmpour; Jeffrey Stoddard; Bruce D Forrest
Journal:  Pediatr Infect Dis J       Date:  2004-11       Impact factor: 2.129

Review 3.  An overview of serum antibody responses to influenza virus antigens.

Authors:  R B Couch
Journal:  Dev Biol (Basel)       Date:  2003

4.  Specific in vitro antibody response to influenza virus by human blood lymphocytes.

Authors:  R E Callard
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

Review 5.  Role of influenza vaccine for healthy children in the US.

Authors:  Stan L Block
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 6.  Immunological memory in humans.

Authors:  Shane Crotty; Rafi Ahmed
Journal:  Semin Immunol       Date:  2004-06       Impact factor: 11.130

7.  In vitro production of anti-influenza virus antibody after intranasal inoculation with cold-adapted influenza virus.

Authors:  R Yarchoan; B R Murphy; W Strober; M L Clements; D L Nelson
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

8.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

9.  Measuring antibody responses to a live attenuated influenza vaccine in children.

Authors:  Min-Shi Lee; Kutubuddin Mahmood; Lopa Adhikary; Marilyn J August; Julie Cordova; Iksung Cho; George Kemble; Keith Reisinger; Robert E Walker; Paul M Mendelman
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129

10.  Influenza-associated hospitalizations in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

View more
  91 in total

Review 1.  Protective B cell responses to flu--no fluke!

Authors:  Elizabeth E Waffarn; Nicole Baumgarth
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

2.  Plasmablast-derived polyclonal antibody response after influenza vaccination.

Authors:  Xiao-Song He; Sanae Sasaki; Carlos F Narvaez; Caiqiu Zhang; Hui Liu; Jennifer C Woo; George W Kemble; Cornelia L Dekker; Mark M Davis; Harry B Greenberg
Journal:  J Immunol Methods       Date:  2010-12-21       Impact factor: 2.303

3.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

4.  Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Alan L Rothman; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-02-26       Impact factor: 3.641

5.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Authors:  Grazia Galli; Duccio Medini; Erica Borgogni; Luisanna Zedda; Monia Bardelli; Carmine Malzone; Sandra Nuti; Simona Tavarini; Chiara Sammicheli; Anne K Hilbert; Volker Brauer; Angelika Banzhoff; Rino Rappuoli; Giuseppe Del Giudice; Flora Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

6.  Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab.

Authors:  Alice Cho; Bridget Bradley; Robert Kauffman; Lalita Priyamvada; Yevgeniy Kovalenkov; Ron Feldman; Jens Wrammert
Journal:  JCI Insight       Date:  2017-06-15

7.  Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization.

Authors:  Jessica L Halliley; Shuya Kyu; James J Kobie; Edward E Walsh; Ann R Falsey; Troy D Randall; John Treanor; Changyong Feng; Ignacio Sanz; F Eun-Hyung Lee
Journal:  Vaccine       Date:  2010-03-16       Impact factor: 3.641

8.  Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies.

Authors:  Sanae Sasaki; Meghan Sullivan; Carlos F Narvaez; Tyson H Holmes; David Furman; Nai-Ying Zheng; Madhuri Nishtala; Jens Wrammert; Kenneth Smith; Judith A James; Cornelia L Dekker; Mark M Davis; Patrick C Wilson; Harry B Greenberg; Xiao-Song He
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

Review 9.  Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.

Authors:  Natalie J Carter; Monique P Curran
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

10.  Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells.

Authors:  Shuya Y Kyu; James Kobie; Hongmei Yang; Martin S Zand; David J Topham; Sally A Quataert; Ignacio Sanz; F Eun-Hyung Lee
Journal:  J Immunol Methods       Date:  2008-11-06       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.